China Resources Pharma's subsidiary China Resources Boya Biology earned 113 million RMB for the year, a decline of 71.6%

China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources Boya Biology (300294.SZ) achieved an operating revenue of 2.059 billion RMB for the fiscal year 2025, an increase of 18.7% year-on-year. The net profit attributable to shareholders was 113 million RMB, a decline of 71.6%, with earnings per share of 0.22 RMB. A dividend of 0.73 RMB per 10 shares will be distributed